Kimberly-Clark's $48.7 Billion Tylenol Acquisition: A Buying Opportunity Amidst Legal Risks

Kimberly-Clark Corp. has made a $48.7-billion takeover offer for Tylenol maker Kenvue Inc., despite the company's struggles with a declining share price and concerns over acetaminophen's link to autism. The deal creates an intriguing buying opportunity for investors, with a beaten-up share price and an attractive dividend. However, the acquisition also inherits potential legal complications from Trump's warnings about Tylenol's risks.